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1Introduction
Despite significant advancements in cancer therapeutics, 
residual disease and pan- resistance (i.e., against any 
available chemotherapies and radiotherapy) remain a 
persistent problem in many patients [1]. The concept 
of cancer stem cells (CSCs, also termed cancer- initiating 
cells) was proposed as a responsible factor for residual 
disease [2,3]. CD44v9, one of the best- characterized 
surface antigens of CSCs, interacts with cystine/glutamate 
transporter for cystine uptake [4, 5]. A continual cystine 
supply is crucial for de novo synthesis of glutathione 
and thioredoxin antioxidant peptides, highlighting 
CD44v9’s role in redox regulation [4, 5]. The transcrip-
tion factor NRF2 (encoded by the NFE2L2 gene), a 
master regulator against oxidative stress, shows 
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Abstract
NRF2 stabilizes redox potential through genes for glutathione and thioredoxin 
antioxidant systems. Whether blockade of glutathione and thioredoxin is useful 
in eliminating cancer stem cells remain unknown. We used xenografts derived 
from colorectal carcinoma patients to investigate the pharmacological inhibition 
of glutathione and thioredoxin systems. Higher expression of five glutathione 
S- transferase isoforms (GSTA1, A2, M4, O2, and P1) was observed in xenograft- 
derived spheroids than in fibroblasts. Piperlongumine (2.5–10 μmol/L) and 
auranofin (0.25–4 μmol/L) were used to inhibit glutathione S- transferase π and 
thioredoxin reductase, respectively. Piperlongumine or auranofin alone up- 
regulated the expression of NRF2 target genes, but not TP53 targets. While 
piperlongumine showed modest cancer- specific cell killing (IC50 difference be-
tween cancer spheroids and fibroblasts: P = 0.052), auranofin appeared more 
toxic to fibroblasts (IC50 difference between cancer spheroids and fibroblasts: 
P = 0.002). The synergism of dual inhibition was evaluated by determining 
the Combination Index, based on the number of surviving cells with combina-
tion treatments. Molar ratios indicated synergism in cancer spheroids, but not 
in fibroblasts: (auranofin:piperlongumine) = 2:5, 1:5, 1:10, and 1:20. Cancer- 
specific cell killing was achieved at the following drug concentrations 
(auranofin:piperlongumine): 0.25:2.5 μmol/L, 0.5:2.5 μmol/L, or 0.25:5 μmol/L. 
The dual inhibition successfully decreased CD44v9 surface presentation and 
delayed tumor emergence in nude mouse. However, a small subpopulation 
persistently survived and accumulated phosphorylated histone H2A. Such “per-
sisters” still retained lesser but significant tumorigenicity. Thus, dual inhibition 
of glutathione S- transferase π and thioredoxin reductase could be a feasible 
option for decreasing the tumor mass and CD44v9- positive fraction by disrupt-
ing redox regulation.
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tumor- specific nuclear localization as well as phospho-
rylation in surgical specimens of hepatocellular carcinoma 
(HCC) [6]. It activates a battery of antioxidant genes 
classified into three subgroups: glutathione system, thiore-
doxin system, and NADPH production [7–9]. Of note, 
levels of the enzymes of the pentose phosphate pathway 
(PPP), a major source of NADPH, increase in surgical 
specimens of colorectal carcinomas (CRCs) [10]. The 
significance of augmented NADPH production is in the 
recycling of glutathione and thioredoxin antioxidant 
peptides (Fig. S1). Thus, both glutathione and thiore-
doxin depend on NADPH’s reducing power to continually 
recycle their antioxidant functions (Fig. S1). NRF2, as 
a redox sensor and feedback regulator, integrates three 
groups of enzymes (those associated with the glutathione 
and thioredoxin systems and NADPH production) to 
reduce reactive oxygen species (ROS) [9]. Hence, NRF2 
stabilizes intracellular redox potential and ensures robust 
cellular systems against potential harmful effects of ROS. 
For example, once the glutathione system is disrupted 
(e.g., by pharmacological inhibition), increased ROS 
activates NRF2, and subsequently, the other thioredoxin 
system is augmented for compensation. Indeed, combined 
inhibition of glutathione and thioredoxin systems syn-
ergizes to kill cancer cells [11], suggesting the existence 
of mutually compensatory mechanisms. Whether such 
a combination strategy is useful for eliminating CSCs, 
specifically to eradicate residual diseases, remains 
unknown. Accumulating evidence indicate that pharma-
cological inhibition against ROS protection system is 
indeed a promising anticancer strategy [12, 13]. 
Importantly, such approach appears to be effective irre-
spective of TP53 status [12, 13], suggesting that elevating 
ROS could kill cancer cells with diverse array of muta-
tional profiles.
In this study, we investigated the pharmacological inhi-
bition against glutathione, thioredoxin, or PPP using CRC 
patient- derived xenograft tumor cells. Pharmacological 
inhibition against glutathione S- transferase (GST)π or 
thioredoxin reductase (TXNRD) up- regulated the expres-
sion of NRF2 target genes, but not of TP53 target genes, 
in CRC spheroids. Dual inhibition of GSTπ and TXNRD 
synergistically caused cell death and the synergism was 
more remarkable in CRC spheroids than in normal fibro-
blasts. Dual inhibition successfully decreased CD44v9 
surface presentation and delayed tumor emergence in nude 
mouse. A small subpopulation of CRC spheroids showed 
accumulated double- strand DNA breaks but nevertheless 
retained lesser but significant tumorigenicity. Therefore, 
dual inhibition of GSTπ and TXNRD is a feasible option 
for decreasing the tumor burden and CD44v9- positive 
fraction. However, this approach could potentially fail to 
eliminate residual disease.
Materials and Methods
Patients and biospecimens
This study was approved by the Institutional Review Board 
of Dokkyo Medical University Hospital (ID: 26015), on 
the basis of the Ethical Guidelines for Clinical Research 
of the Ministry of Health, Labor and Welfare, Japan. 
Patients who were diagnosed as having CRC at Dokkyo 
Medical University Hospital agreed to donate the surgi-
cally resected tumor specimens for research purposes.
Tumor serial transplantation in nude mice
All experimental procedures were approved by the animal 
facility at Dokkyo Medical University (ID: 951) and were 
described elsewhere [10]. The existence of CSCs has been 
experimentally proven through serial xenotransplantation 
and tumorigenesis [2, 14]. In order to obtain a tractable 
model of colorectal CSCs, we subcutaneously xenotrans-
planted tumors derived from 72 CRC patients, among 
that 20 specimens formed tumors after 1–4 months. These 
subcutaneous tumors were again subjected to enzymatic 
dissociation and some of the tumor cells were subcutane-
ously transplanted into other mice. The tumor cells, con-
taining a sufficient number of colorectal CSCs, were 
successfully transplanted more than three times in 12 cases. 
We confirmed that such tumors contained a substantial 
number of CD44v9- positive cells (a known CSC marker 
[5, 15]). CD44v9- positive rate was stable for at least 1 week 
(data not shown), even after dissociated tumors had been 
cultured as spheroids in vitro (cancer tissue- originated 
spheroids: CTOS). Therefore, we maintained patient- 
derived xenografts in vivo and used primary culture of 
CTOSs as accessible model of colorectal CSCs. Seven cases 
(CTOS:40, 42, 68, 71, 76, 86, 88) were used for in vitro 
experiments.
Cell culture
Modified procedures of CTOS culture [16] were described 
elsewhere [10]. Enzymatically dissociated cancer cell clumps 
formed spheroids in low- adhesion cell culture dishes 
 (Ez- BindShut II, Iwaki, Tokyo, Japan) with almost 100% 
success rate. The culture medium was serum- free advanced 
DMEM/F- 12 (GIBCO, Waltham, MA) supplemented with 
FGF- 2 (10 ng/mL, ReproCell, Yokohama, Japan), penicillin 
(100 mg/mL, Wako, Osaka, Japan), streptomycin (0.1 mg/mL, 
Wako), gentamicin (50 μg/mL, Wako), and fungizone 
(0.25 μg/mL, GIBCO). DLD- 1 and HCT116 CRC cell lines 
were purchased from JCRB Cell Bank (Osaka, Japan) and 
RIKEN BioResource Center (Ibaraki, Japan), respectively. 
In order to estimate pharmacological side effects against 
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normal tissues, human diploid fibroblasts were purchased 
(JCRB Cell Bank) as model cells. The origins of the fibro-
blasts were as follows: OUMS- 36 (embryo), TIG- 3 (fetal 
lung), TIG- 111 (dermal fibroblasts [DFs] from 6- year- old 
individual), TIG- 119 (DFs from 34- year- old individual), 
and TIG- 102 (DFs from 97- year- old individual). Adult 
DFs were purchased from Kurabo (Osaka, Japan). CRC 
cell lines and fibroblasts were maintained under supplier- 
recommended culture conditions. Since the culture condi-
tions are different between fibroblasts and CTOSs, we 
need to be cautious about the interpretation of data (i.e., 
lateral comparison between them). Indeed, we encountered 
some discrepancy about drug sensitivity between conven-
tional cancer cell lines (adherent culture [12]) and CTOSs 
(spheroid culture, in this study). However, most CTOS 
cells rarely attach on plastic dish and oppositely, spheroid 
culture of fibroblasts compromised cell survival (data not 
shown). Colorectal CTOSs display augmented survival 
through maintaining epithelial structure with E- cadherin 
[16]. On the other hand, the establishment of conventional 
cell lines (adherent culture) are much less efficient because 
constant cell division and autonomous survival are required 
for the procedure. When we choose CTOSs instead of 
cancer cell lines, we lose the equivalent condition (adher-
ent culture) as a trade- off.
Reagents
The strategy for pharmacological inhibition of redox regu-
lation systems is as follows (Fig. S1): Piperlongumine 
(Sigma- Aldrich, St. Louis, MO) is a plant alkaloid [17] 
and selectively kills cancer cells over normal cells [12, 18]. 
One of its molecular targets is GSTπ (encoded by the 
GSTP1 gene) [12], one of the five up- regulated isoforms 
in CRC CTOSs (Fig. 1). Auranofin (Sigma- Aldrich) is a 
clinically approved drug for rheumatoid arthritis and con-
sidered to inhibit TXNRD [9, 11, 19]. CB83 (ChemBridge, 
San Diego, CA) is a newly identified glucose- 6- phosphate 
dehydrogenase (G6PD) inhibitor and inhibits PPP activity 
(G6PD is a critical enzyme for PPP) [10, 20].
Immunocytochemistry
To validate the specificity of the above pharmacological 
intervention against CSCs, CRC CTOSs were dual stained 
with CD44v9 antibody (mouse monoclonal, Cosmobio, 
Tokyo, Japan) and GSTP1 (rabbit monoclonal, #138491, 
Abcam, Cambridge, UK) or TXNRD1 antibody (rabbit 
monoclonal, #167411, Abcam). CTOSs were fixed with 
4% paraformaldehyde (Wako) for 30 min and rinsed with 
PBS, cryoprotected in 10–30% sucrose, and embedded in 
OCT (Sakura Finetech Japan, Tokyo, Japan). The CTOSs 
were cryosectioned with a thickness of 12 μm. Slides were 
rehydrated in PBS and were reacted with the primary 
antibodies. Subsequently, secondary antibodies conjugated 
with Alexa Fluor®488 (#A28175, Molecular Probes, 
Waltham, MA) and with Alexa Fluor®594 (#150084, Abcam) 
were used to visualize primary antibodies’ localizations 
(Fig. S2). Fluorescent photos were taken by confocal 
microscopy (FV10i, Olympus, Tokyo, Japan). Both GSTP1 
and TXNRD1 were colocalized with CD44v9 at poorly 
organized mesenchymal structure of CTOSs, but not at 
organized epithelial structure (Fig. S2). Data indicate that 
both target enzymes are abundantly synthesized at CSCs.
Flow cytometry
In order to estimate the effect of each inhibitor described 
above, intracellular reactive oxygen species (ROS) were 
Figure 1. Five classes of glutathione S- transferase are up- regulated in 
colorectal cancer tissue- originated spheroids (CTOSs), whereas three 
classes are down- regulated. mRNA expression of each gene was 
quantified by real- time RT- PCR and expression level was indicated as 
relative Log2 expression. Black and gray box plots represent fibroblasts 
(embryonic or dermal) and CTOSs (from distinct colorectal carcinomas 
patients), respectively. (A) GST isoforms up- regulated in colorectal 
CTOSs compared to fibroblasts. (B) GST isoforms down- regulated 
in colorectal CTOSs compared to fibroblasts. GST, glutathione 
S- transferase; DF, TIG111, and 119, dermal fibroblasts; TIG3 and 
OUMS36, embryonic fibroblasts.
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measured using CellROX™ Deep Red reagent (Molecular 
Probes). Briefly, cells were seeded on 6- well plates at 1 × 106 
cells per well. After cells reached 90% confluence, cells were 
treated with designated reagents for 1 h. CellROX™ Deep 
Red reagent was added at a final concentration of 5 μmol/L 
to the culture medium and then incubated for 30 min at 
37°C. Subsequently, the medium was removed and the cells 
were washed with PBS and detached using 0.25% trypsin- 
EDTA. The resulting fluorescence was measured using a 
FACS Calibur flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ). Menadione (100 μmol/L) was added 30 min 
before CellROX™ Deep Red reagent treatment as a reference 
ROS inducer. Embryonic fibroblasts OUMS- 36 and TIG- 3 
showed higher levels of basal ROS but displayed poor response 
(i.e., no ROS increase) against menadione, CB83, and piper-
longumine (Fig. S3). DLD- 1 and HCT116 showed lower 
levels of basal ROS but displayed good response (i.e., increase 
of ROS) against menadione, CB83 (for HCT116), auranofin 
(for HCT116 and DLD- 1), and piperlongumine (for HCT116, 
Fig. S3). CD44v9 positivity of CTOS cells was analyzed as 
follows: Cancer spheroids were dispersed with serial treat-
ments of TrypLE™ (20 min, GIBCO) and Accumax™ (10 min, 
Innovative Cell Technologies, San Diego, CA). Cell surface 
CD44v9 was stained with CD44v9 antibody (Cosmobio) as 
well as PE- conjugated anti- rat IgG2a (Becton Dickinson). 
The fluorescence was measured using a FACS Calibur flow 
cytometer (Becton Dickinson). Since CTOSs contained abun-
dant auto- fluorescent cells, we defined FL2+FL1− cells as 
authentic PE- positive (Fig. S4). Thus, CD44v9- positive rate 
was defined as FL2+FL1−/total live cells and CD44v9- positive 
fraction was further gated and split between CD44v9low and 
CD44v9high (Fig. S4), to calculate the mean fluorescent 
intensity of CD44v9high fraction.
Quantitative reverse transcription 
polymerase chain reaction
Total RNA was purified using RNAiso Plus (Takara, Osaka, 
Japan). Reverse transcription was performed using 
PrimeScript™ with gDNA Eraser (Takara). For quantifying 
the copy number of each mRNA, we used a StepOne™ 
Real- Time PCR System (Applied Biosystems, Waltham, 
MA) and the Taqman® method. Data were calculated 
according to the modified delta- cycle of threshold (ΔCT) 
method. Normalized Log2 expression was defined as fol-
lows: (Log2 expression of a gene of interest) = 30 (arbitrary 
constant) + (CT of 18S rRNA) − (CT of a gene of inter-
est). We used Log2 parameter for statistical analysis because 
mRNA expression follows a log- normal distribution, 
whereas ΔCT follows normal distribution. A gene- specific 
fluorescent probe was designed using a web- based program 
(https://qpcr.probefinder.com/organism.jsp). Table S1 
SpreadSheet1 shows the primer sequences and 
corresponding fluorescent probes. Gene- specific Taqman® 
probes were purchased from Life Technologies, (Waltham, 
MA, for Cat#, see Table S1 SpreadSheet2). For PCR, 
Thunderbird® Probe qPCR mix (Toyobo, Osaka, Japan) 
was used and the PCR conditions consisted of 40 cycles 
of two steps (95°C for 15 sec and 60°C for 50 sec).
Determination of half- maximal inhibitory 
concentration and combination index
Each drug’s half- maximal inhibitory concentration (IC50) 
was calculated based on live cell number ratios (drug 
treated/untreated × 100%) obtained from serial dilution 
of drug concentration. The length of drug exposure was 
5 days. Each number of live cells was counted automati-
cally by trypan blue exclusion (LUNA automated cell 
counter, Logos Biosystems, Anyang, South Korea). Cancer 
spheroids were dispersed with serial treatments (20 min 
each) of TrypLE™ and Accumax™. Thus, IC50 was deter-
mined based on cellular survival, but not on proliferation. 
We chose the survival index instead of the speed of growth 
because CTOSs in vitro show very slow proliferation (qui-
escence), which is one of the hallmarks of CSCs [2]. The 
IC50 values of fibroblasts were accordingly determined 
based on cellular survival index during quiescence (by 
contact inhibition). However, it was difficult to precisely 
control cellular density due to gradual increase in cell 
size (senescence, data not shown). As a result, the vari-
ance of cellular survival was greater in fibroblasts compared 
to CTOSs (Fig. 6). To quantify the synergism of two 
distinct drugs, Combination Index (CI) was calculated 
[21]. A CI value of about 1 (0.90–1.10) was defined as 
nearly additive and CI values more than (>1.10) and less 
than (<0.90) were defined as antagonism and synergism, 
respectively. IC50 and CI were determined using CompuSyn 
software (ComboSyn, Paramus, NK).
Statistical analysis
Comparison between two groups (fibroblasts vs. CTOSs) 
and statistical differences in mean values (Log2 expression 
for GST isoforms, IC50 value, or CIs) were determined 
by t test using Excel software (Microsoft, Redmond, WA). 
Either Student’s t or Welch’s t test was used according 
to the homoscedasticity of two groups (determined by 
F- test of Excel). The variance of cellular survival at dif-
ferent passage points (fibroblasts or CTOSs) was analyzed 
using SPSS (Levene’s test, IBM, Armonk, NY) and Welch’s 
t test was used to compare survival ratios between fibro-
blasts and CTOSs.
In order to judge the effect of drug treatments on gene 
expression, a repeated measures one- way analysis of vari-
ance (ANOVA) was used to determine the variance of 
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Log2 expression from four different groups (untreated, 
auranofin, CB83, and piperlongumine) using SPSS. 
Subsequently, the effect of each drug was determined by 
a paired t test as a post hoc analysis. The P- values < 0.05 
were defined as statistically significant.
Protein extraction and immunoblotting
From colorectal CTOS, whole- cell proteins were dissolved 
with solubilizer (7 mol/L urea, 2 mol/L thiourea, 2% 
Triton X- 100, Wako) and the entangled genomic DNA 
was sheared by sonication for 30 min. Procedures for 
immunoblotting have been described elsewhere [6, 10]. 
Primary antibodies used in this study are as follows: 
phosphorylated NRF2 from Abcam (#76026) and Histone 
H3 from Cell Signaling Technologies (#4499, Danvers, 
MA). Phosphorylation of NRF2 is well correlated with 
nuclear accumulation in HCCs [6]. Representative data 
are shown in the figures; all experiments were reproduced 
at least twice with different passage points.
Lateral comparison of tumorigenesis in 
nude mice
Seven days after drug treatment in vitro, debris from dead 
cells were removed by vigorous pipetting and brief cen-
trifugation. To enable lateral comparison of tumorigenesis 
between drug- treated or - untreated CTOSs, survived cells 
were injected in left (drug- treated) or right (untreated) 
side of a nude mouse, respectively (Fig. 9B). Since the 
counting of cell number by enzymatic dissociation com-
promises cell survival, the amount of spheroids were 
adjusted with pellet size [10]. No drug was administered 
in vivo during tumor formation. About 3–4 weeks after 
tumor injection and a larger tumor reaches the sufficient 
size, mice were killed and tumors were collected and 
weighed.
Results
Differential expression of 17 classes of GST 
between colorectal cancer tissue- originated 
spheroids and fibroblasts
To determine the pharmacological target of glutathione 
system, we compared the expression levels of 17 classes 
of GST between colorectal CTOS and fibroblasts. The 
normalized ΔCT for GSTA1, A2, A3, A4, A5, K1, M1, 
M2, M3, M4, M5, O1, O2, P1, T1, T2, and Z1 were 
determined by quantitative RT- PCR (Table S2). Compared 
to fibroblasts, colorectal CTOSs showed up- regulation of 
five classes of GST (GSTA1, GSTA2, GSTM4, GSTO2, 
and GSTP1) (Fig. 1, Table S2) and down- regulation of 
three classes (GSTM3, GSTO1, and GSTT2) (Fig. 1, Table 
S2). Among them, we chose GSTπ (encoded by the GSTP1 
gene) as a cancer- specific target of glutathione system.
Target genes of NRF2, but not of TP53 were 
up- regulated by pharmacological inhibition 
of TXNRD or GSTπ in colorectal CTOSs
In order to estimate NRF2 compensation induced by 
pharmacological inhibition of TXNRD (auranofin), G6PD 
(CB83), or GSTπ (piperlongumine), we quantified gene 
expression of NRF2 target genes. Activation of NRF2 
protein was confirmed by NRF2 phosphorylation (Fig. 
S5A). The Log2 expression for each gene with or without 
each inhibitor is presented in Figures 2–4.
Glutathione system
NRF2 up- regulates GCLC and GCLM genes, components 
of glutathione system. The significance of expression changes 
due to exposure to a higher dose (above IC50) for auranofin 
(4 μmol/L), CB83 (25 μmol/L), and piperlongumine 
(10 μmol/L) for 24 h were as follows: GCLC (Fig. 2A, 
P = 0.055 by ANOVA) and GCLM (Fig. 2C, Aura: P = 0.045, 
up- regulated, CB: P = 0.071, Pipe: P = 0.029, up- regulated). 
The significance of expression changes due to exposure 
to a lower dose (below IC50) for auranofin (2 μmol/L), 
CB83 (12.5 μmol/L), and piperlongumine (5 μmol/L) for 
48 h were as follows: GCLC (Fig. 2B, Aura: P = 0.006, 
up- regulated, CB: P = 0.699, Pipe: P = 0.17) and GCLM 
(Fig. 2D, Aura: P = 0.002, up- regulated, CB: P = 0.479, 
Pipe: P = 0.042, up- regulated).
Thioredoxin system
NRF2 up- regulates PRDX1, TXN, and TXNRD1 genes, com-
ponents of thioredoxin system. The significance of expression 
changes due to exposure to a higher dose for 24 h were 
as follows: PRDX1 (Fig. 3A, P = 0.106 by ANOVA), TXN 
(Fig. 3C, P = 0.137 by ANOVA), and TXNRD1 (Fig. 3E, 
Aura: P = 0.021, up- regulated, CB: P = 0.007, up- regulated, 
Pipe: P = 0.007, up- regulated). The significance of expres-
sion changes due to exposure to a lower dose for 48 h 
were as follows: PRDX1 (Fig. 3B, Aura: P = 0.066, CB: 
P = 0.766, Pipe: P = 0.115), TXN (Fig. 3D, Aura: P = 0.011, 
up- regulated, CB: P = 0.851, Pipe: P = 0.096), and TXNRD1 
(Fig. 3F, Aura: P = 0.009, up- regulated, CB: P = 0.154, 
Pipe: P = 0.016, up- regulated).
NADPH production
NRF2 up- regulates G6PD, IDH1, and ME1 genes, enzymes 
for NADPH production. The significance of expression 
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changes due to exposure to a higher dose for 24 h were 
as follows: G6PD (Fig. 4A, Aura: P = 0.009, up- regulated, 
CB: P = 0.099, Pipe, P = 0.002, up- regulated), IDH1 
(Fig. 4C, P = 0.566 by ANOVA), and ME1 (Fig. 4E, 
P = 0.0807 by ANOVA). The significance of expression 
changes due to exposure to a lower dose for 48 h were 
as follows: G6PD (Fig. 4B, Aura: P = 0.001, up- regulated, 
CB: P = 0.659, Pipe: P = 0.009, up- regulated), IDH1 
(Fig. 4D, P = 0.037 by ANOVA), and ME1 (Fig. 4F, 
Aura: P = 0.017, up- regulated, CB: P = 0.705, Pipe: 
P = 0.148).
NRF2 compensation in fibroblasts
To investigate whether NRF2 compensation occurs in 
fibroblasts, we quantified gene induction of NRF2 target 
genes by auranofin (2 μmol/L for 24 h) or piperlongumine 
(5 μmol/L for 24 h). NRF2 protein was weekly phospho-
rylated by auranofin, but not by piperlongumine (Fig. 
S5A). Basal phosphorylation of NRF2 was lower in fibro-
blasts, compared to CTOSs (Fig. S5B). The Log2 expression 
for each gene with or without each inhibitor is presented 
in Fig. S6. The significance of expression changes due to 
the exposure were as follows: GCLM (Fig. S6, Aura: 
P = 0.001, up- regulated, Pipe: P = 0.009, up- regulated), 
TXNRD1 (Fig. S6, Aura: P = 0.001, up- regulated, Pipe: 
P = 0.439), and G6PD (Fig. S6, Aura: P = 0.001, 
 up- regulated, Pipe: P = 0.130).
TP53 targets
TP53 up- regulates BBC3 (PUMA) and CDKN1A 
(P21CIP1). The significance of expression changes due to 
exposure to a higher dose were as follows: BBC3 (CTOSs: 
Fig. S7A, P = 0.345 by ANOVA) and CDKN1A (CTOSs: 
Fig. S7C, P = 0.497 by ANOVA). The significance of 
expression changes due to exposure to a lower dose were 
as follows: BBC3 (fibroblasts: Fig. S6, Aura: P = 0.031, 
Pipe: P = 0.001, up- regulated; CTOSs: Fig. S7B, P = 0.757 
by ANOVA) and CDKN1A (fibroblasts: Fig. S6, Aura: 
P = 0.036, Pipe: P = 0.730; CTOSs: Fig. S7D, P = 0.141 
by ANOVA). Although we failed to detect any significant 
effect by drug treatment in CTOSs, ANOVA revealed 
individual differences among patients (i.e., some patients 
retained TP53 activity but the other not, P < 0.001) for 
both BBC3 and CDKN1A.
Dual inhibition of TXNRD and GSTπ 
displayed synergistic cell death of colorectal 
CTOSs but the synergism was not 
remarkable in fibroblasts
qRT- PCR data suggest that auranofin or piperlongumine 
successfully increased intracellular ROS and the subsequent 
activation of NRF2 compensated the inhibition. To confirm 
that glutathione and thioredoxin compensate for each 
other through NRF2, we combined auranofin and 
Figure 2. Pharmacological inhibition of redox regulation up- regulated NRF2 target genes (glutathione system) in colorectal cancer tissue- originated 
spheroids (CTOSs). Colorectal CTOSs were incubated with designated concentration of inhibitor. mRNA expression of each gene was quantified by 
real- time RT- PCR and expression level was indicated as relative Log2 expression. Each plot indicates Log2 expression of each CTOS (i.e., data from 
distinct patients). (A and B) Expression of GCLC. (C and D) Expression of GCLM. (A and C) Drug exposure for 24 h. (B and D) Drug exposure for 48 h. 
Asterisk denotes significant difference from untreated group. Aura: auranofin (TXNRD inhibitor), CB: CB83 (G6PD inhibitor), Pipe: piperlongumine 
(GSTπ inhibitor).
16 18 20 22 24 26
Pipe 5 umol/L
CB 12.5 umol/L
Aura 2 umol/L
Untreated
GCLM 48 h
Log2 Expression
14 16 18 20 22 24 26
Pipe 10 umol/L
CB 25 umol/L
Aura 4 umol/L
Untreated
GCLM 24 h
Log2 Expression
18 20 22 24 26
Pipe 10 umol/L
CB 25 umol/L
Aura 4  umol/L
Untreated
GCLC 24 h
Log2 Expression
18 20 22 24 26
Pipe 5 umol/L
CB 12.5 umol/L
Aura 2 umol/L
Untreated
GCLC 48 h
Log2 Expression
*
*
*
*
*
A B
C D
7© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Dual Inhibition of Glutathione and ThioredoxinG. Tanaka et al.
piperlongumine at various molar ratios and quantified 
synergism in CTOSs and fibroblasts. The IC50 value for 
each drug and CIs are summarized in Table 1 (for details, 
see Table S3).
Ic50
As for single usage of each drug, CTOSs are less sensitive 
against auranofin than fibroblasts (Table 1, P = 0.0023). 
However, CTOSs are slightly more sensitive against piper-
longumine (Table 1, P = 0.052).
CIs
Auranofin and piperlongumine displayed synergism against 
CTOSs (Table 1, CI < 0.7). Against fibroblasts, the dual 
inhibition displayed nearly additive (0.9 < CI<1.1) or at 
most, much weaker synergism (0.7 < CI<0.9) compared 
to CTOSs (Fig. 5, Table 1). Significant difference in CI 
was detected at molar ratio 1:20 (P = 0.028), 1:10 
(P = 0.001), 1:5 (P = 0.001), and 2:5 (P = 0.001) (Fig. 5, 
Table 1 and Table S3).
Ratio of surviving cells
In order to ensure that the cytotoxic effect is cancer- 
specific, we compared the ratio of surviving cells against 
three different molar ratios (Fig. 6 and Table S3). The 
first molar ratio was 1:5 (Aura 0.5 μmol/L + Pipe 
2.5 μmol/L, Fig. 6A). CTOSs were more sensitive to 
dual inhibition than fibroblasts (Fig. 6A, P < 0.001 by 
Welch’s t test), but the variance was larger in fibroblasts 
when data were taken from different passage points 
(probability of homoscedasticity = 0.001 by Levene’s 
test). The second molar ratio was 1:10 (Aura 
0.25 μmol/L + Pipe 2.5 μmol/L, Fig. 6B). CTOSs were 
more sensitive to dual inhibition than fibroblasts (Fig. 6A, 
P < 0.001), but the variance was larger in fibroblasts 
Figure 3. Pharmacological inhibition of redox regulation up- regulated NRF2 target genes (thioredoxin system) in colorectal cancer tissue- originated 
spheroids (CTOSs). Colorectal CTOSs were incubated with designated concentration of inhibitor. mRNA expression of each gene was quantified by 
real- time RT- PCR and expression level was indicated as relative Log2 expression. Each plot indicates Log2 expression of each CTOS (i.e., data from 
distinct patients). (A and B) Expression of PRDX1. (C and D) Expression of TXN. (E and F): expression of TXNRD1. (A, C, and E) Drug exposure for 24 h. 
(B, D, and F) Drug exposure for 48 h. Asterisk denotes significant difference from untreated group.
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when compared to CTOSs (P < 0.001). The third molar 
ratio was 1:20 (Aura 0.25 μmol/L + Pipe 5 μmol/L, 
Fig. 6C). CTOSs were more sensitive to dual inhibition 
than fibroblasts (Fig. 6C, P < 0.001), but the variance 
was larger in fibroblasts when compared to CTOSs 
(P = 0.003).
Table 1. Half- maximal inhibitory concentrations (IC50) and Combination Indices (CI) of TXNRD inhibitor and GSTπ inhibitor.
OUMS36 TIG3 TIG111 TIG119 DF TIG102 CTOS71 CTOS76 CTOS86 CTOS88
AuraIC50 1.79 1.96 1.75 1.17 1.59 1.09 2.21 2.83 3.02 2.34
PipeIC50 9.36 10.62 8.04 7.48 6.30 7.89 6.01 7.15 7.12 4.25
CI 
1:20
1.63 1.17 1.11 0.92 0.79 0.25 0.65 0.46 0.90
CI 
1:10
0.73 1.17 0.95 0.98 0.77 0.81 0.19 0.48 0.38 0.47
CI 
1:5
0.82 0.90 0.73 0.90 0.85 1.17 0.24 0.32 0.45 0.56
CI 
2:5
0.78 1.08 0.76 1.04 0.95 0.78 0.34 0.43 0.48
Cells were treated with serial dilution of inhibitors either alone or with combination. IC50 and CI were calculated based on surviving cell number (% 
treated/untreated and for details, see Supplementary Table S3), aided by Compusyn software. CI value around 1 (0.90–1.10) is defined as “nearly 
additive” and CI values more (>1.10) and less (<0.90) are defined as “antagonism” and “synergism”, respectively (see Methods). Unit for IC50: 
μmol/L. CTOSs, cancer tissue-originated spheroids; TXNRD, thioredoxin reductase.
Figure 4. Pharmacological inhibition of redox regulation up- regulated NRF2 target genes (NADPH production) in colorectal cancer tissue- originated 
spheroids (CTOSs). Colorectal CTOSs were incubated with designated concentration of inhibitor. mRNA expression of each gene was quantified by 
real- time RT- PCR and expression level was indicated as relative Log2 expression. Each plot indicates Log2 expression of each CTOS (i.e., data from 
distinct patients). (A and B) Expression of G6PD. (C and D) Expression of IDH1. (E and F) Expression of ME1. (A, C, and E) Drug exposure for 24 h. 
(B, D, and F) Drug exposure for 48 h. Asterisk denotes significant difference from untreated group.
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A small subpopulation of CTOS showed 
persistent survival against TXNRD/GSTπ dual 
inhibition and accumulated double- strand 
DNA breaks
Comparison of IC50 values between fibroblasts and CTOSs 
indicate that drug treatment could reduce the size of the 
bulk tumor but could not eliminate all the cancer cells, 
in realistic therapeutic concentrations (e.g., Aura 
0.25 μmol/L + Pipe 2.5 μmol/L). Indeed, we noted that 
a small number of CTOS cells persistently survive even 
after prolonged incubation with a higher dose (e.g., Aura 
1 μmol/L + Pipe 10 μmol/L), at which most fibroblasts 
were eliminated. We therefore collected such persisters 
and examined the drugs’ effect for double- strand (ds) 
DNA breaks, a downstream event caused by ROS induc-
tion [22]. Seven days after drug exposure, a dose- dependent 
increase in H2A.X (termed also as γH2AX, phosphorylated 
histone H2A, a surrogate marker of dsDNA break) was 
observed in CTOS cells (Fig. 7). Signal of H2A.X was 
not apparent during 1 or 3 days of drug treatments (Fig. 
S8), suggesting that dsDNA breaks accumulate over time, 
after cells endured the rapid cell death by oxidative stress. 
The effect of drug exposure on total protein synthesis of 
histone H2A and histone H3 was negligible (Fig. 7).
TXNRD/GSTπ dual inhibition decreased 
CD44v9- positive rate of CTOSs
Persistent survival of CTOS cells suggest the existence of 
remaining CSCs. To estimate the efficacy of the drug 
treatment against CSCs, we measured a positive rate of 
CD44v9 with flow cytometry. The molar ratio 1:20 (Aura 
0.25 μmol/L + Pipe 5 μmol/L) as well as 1:10 (Aura 
0.5 μmol/L + Pipe 5 μmol/L) decreased the CD44v9- positive 
rate (Fig. 8A, P = 0.032 for 1:20 and P = 0.015 for 1:10 
Figure 5. Dual inhibition of GSTπ and TXNRD results in synergistic cell 
death in colorectal cancer tissue- originated spheroids (CTOSs). Cells 
were treated with auranofin and piperlongumine. Box plot indicates 
Combination Indices (CI) with molar ratios (auranofin:piperlongumine) 
from 1:20 to 2:5. Black and gray boxes represent fibroblasts (embryonic 
or dermal) and CTOSs (from distinct CRC patients), respectively. A 
perpendicular gray pillar is located around CI from 0.9 to 1.1, where 
dual inhibition displays “nearly additive” effect. CIs to the left of the 
pillar (<0.9) signify “synergism”. The lower the CI, the stronger the 
synergism. Asterisk denotes significant difference between CTOSs and 
fibroblasts.
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Figure 6. Selective killing of colorectal cancer tissue- originated 
spheroids (CTOS) cells by dual inhibition of GSTπ and TXNRD. Colorectal 
CTOSs or fibroblasts were incubated with designated concentration of 
each inhibitor (molar ratio: A: 1:5, B: 1:10, and C: 1:20). Scatter plots 
indicate calculated percentage of survived cells (drugs treated/
untreated). Experiments were repeated with different passage points. 
Note that colorectal CTOSs are more “sensitive” to drugs’ treatment 
than fibroblasts are, indicating selective killing of cancer cells. Error bar 
represents mean ± standard error of the mean. OUMS36 and TIG3: 
embryonic fibroblasts, TIG119, 111, 102 and DF, dermal fibroblasts. 
Asterisk denotes significant difference between CTOSs and embryonic 
fibroblasts. TXNRD, thioredoxin reductase.
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by paired t). Mean fluorescent intensity of CD44v9high 
population was also decreased by TXNRD/GSTπ dual 
inhibition (Fig. 8B, P = 0.037 for 1:20 and P = 0.031 
for 1:10).
TXNRD/GSTπ dual inhibition delayed tumor 
formation
After TXNRD/GSTπ dual inhibition in vitro, survived 
CTOS cells still retained spheroid structure (Fig. 9A). To 
estimate the significance of such “persisters” for residual 
disease, we compared tumor formation between untreated 
and drug- treated (Aura 0.5 μmol/L + Pipe 5 μmol/L) 
CTOSs (Fig. 9B). While untreated CTOSs formed visible 
tumors with approximately 1 week, drug pretreated CTOSs 
did not form tumors until 2 or 3 weeks after injection. 
As a result, tumor weight was heavier in untreated group 
compared to drug- treated group at the point of tumor 
collection (Fig. 9C and D, P = 0.008 by paired t, n = 8). 
In one case, the drug pretreatment abrogated tumor emer-
gence completely (Fig. 9C).
Discussion
One of molecular bases of radiation or conventional 
chemotherapy is thought to be increase in intracellular 
ROS [23]. In general, cancer cells produce abundant ROS 
owing to oncogene activation and proliferation, simultane-
ously maximizing ROS protection by NRF2 activation [24]. 
In addition, cancer cells obtain energy without the aid 
of mitochondria, one of the major sources of intracellular 
ROS (Warburg effect [25, 26]). On top of that, CSCs 
protect themselves through maintaining cellular redox 
potential lower than their differentiated progeny [22]. 
Thus, cancer cells routinely spend majority of their 
resources for redox regulation, rendering them vulnerable 
against further ROS insults, possibly explaining why radia-
tion or chemotherapy is effective despite the apparent 
nonspecificity [23]. Therefore, inhibiting this ROS protec-
tion system is one of the promising approaches to eradicate 
CSCs [9].
Using patient- derived colorectal CTOSs and their xeno-
grafts [10], we made several discoveries. First, five GST 
Figure 7. Prolonged incubation of GSTπ/TXNRD inhibitors induces drug 
resistance and double- strand DNA breaks in colorectal cancer tissue- 
originated spheroids (CTOS) cells. Colorectal CTOS cells were incubated 
with designated molar ratio and serial increment of two inhibitors for 
7 days. Although majority of CTOS cells were killed during prolonged 
exposure to drugs, small number of cells display drug resistance. Whole- 
cell proteins were extracted from such “persisters” and each well was 
loaded with same amount of proteins (20 μg for H2A.X, 30 μg for H2A, 
and 10 μg for H3). Phosphorylation of histone H2 (H2A.X, a marker of 
double- strand DNA breaks) was visualized by western blotting. Blotting 
for histone H2A and H3 serve as loading controls. TXNRD, thioredoxin 
reductase.
Figure 8. Dual inhibition of GSTπ and TXNRD decreased CD44v9 surface presentation of colorectal cancer tissue- originated spheroids (CTOSs). 
Colorectal CTOSs were incubated with designated concentration of each inhibitor (molar ratio 1:20 or 1:10). Enzymatically dispersed cells were 
stained CD44v9 antibody and the cell surface fluorescent signal was analyzed with flow cytometry. (A) CD44v9- positive rate (see Fig. S4 for gating 
strategy). (B) Mean fluorescent intensity of CD44v9high population (Fig. S4). Asterisk denotes significant difference between untreated and dual 
inhibition (paired t).
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isoforms (GSTA1, A2, M4, O2, and P1) are up- regulated 
in colorectal CTOSs relative to fibroblasts. Second, phar-
macological inhibition of GSTπ (GSTP1) or TXNRD 
 up- regulated NRF2 target genes, but not TP53 targets, in 
CTOSs. Third, dual inhibition of GSTπ and TXNRD 
synergistically killed CTOS cells and the synergism was 
observed preferentially in CTOSs and not in fibroblasts. 
Fourth, a small subpopulation of CTOSs persistently sur-
vived the dual inhibition and a marker of double- strand 
DNA breaks was increased in such population. Fifth, the 
dual inhibition successfully decreased surface presentation 
of CD44v9. Sixth and finally, the dual inhibition delayed 
the tumor emergence in vivo but the “persisters” still 
retain tumorigenicity.
We chose one of the GST isoforms as the pharmaco-
logical target of glutathione system. GST has 17 isoforms 
and we have described the differential expression profile 
between colorectal CTOSs and fibroblasts (Fig. 1). 
Piperlongumine selectively kills cancer cells and increase 
intracellular ROS [12]. Since GSTπ is one of the molecular 
targets of piperlongumine, we expected that selective kill-
ing would be reproduced in colorectal CTOS cells. However, 
the difference in IC50 (CTOSs vs. fibroblasts) of piper-
longumine was moderate (P = 0.052, Table S3), indicating 
that the pharmacological window of selective killing is 
not wide enough. This could be due to the augmented 
feedback regulation of NRF2 because piperlongumine 
 up- regulated the genes for thioredoxin system and NADPH 
production in colorectal CTOSs (Figs. 3, 4 and S5). The 
reason for discrepancy between the previous report and 
ours remains clear; it could be due to difference in cell 
culture conditions (see Methods). On the other hand, we 
found that TXNRD inhibition is more toxic against fibro-
blasts than against CTOSs (Tables 1 and S3). In CTOSs, 
auranofin up- regulated the genes for glutathione system 
and NADPH production (Figs. 2 and 4), suggesting that 
CTOSs are more resilient against thioredoxin inhibition 
due to NRF2 feedback. Pharmacological inhibition of criti-
cal enzyme for PPP (G6PD) had negligible effects in terms 
of NRF2 feedback, with the exception of TXNRD1 induc-
tion at 24 h. Previously, we found that G6PD inhibitor 
CB83 reproducibly decreased NADPH/NADP+ ratios, but 
failed to alter GSH/GSSG ratios in CRC cell lines [10]. 
While the compensation mechanisms remain unknown, 
other NADPH production pathway [27] could be involved 
in NRF2- independent manner.
Based on the above observations, we hypothesized that 
mutually compensating glutathione and thioredoxin sys-
tems should be blocked simultaneously to eliminate cancer 
cells. Recently Harris et al. reported that combined inhi-
bition of both systems leads to synergistic cancer cell 
death in vitro and in vivo [11]. They used sulfasalazine, 
buthionine sulfoximine (BSO), and auranofin to inhibit 
cystine/glutamate transporter, glutamate–cysteine ligase 
(GCL), and TXNRD, respectively. The study was the first 
proof- of- concept and we have subsequently designed 
experiments to confirm the feasibility. We adopted a 
“Combination Index” to quantify the synergism of two 
drugs [21] and used several fibroblasts to estimate side 
effects against normal cells. Auranofin and piperlongumine 
exhibited stronger synergism in colorectal CTOSs than 
in fibroblasts at molar ratios 2:5, 1:5, 1:10, and 1:20 
(Fig. 5). There exist drug concentration windows wherein 
substantial numbers of CTOSs, and not fibroblasts, were 
killed (Fig. 6). Although Harris et al. did not compare 
the IC50 and the synergism between cancer and normal 
cells [11], combining BSO and auranofin could induce 
intolerable side effects. This is because, unlike GST, GCL 
has a few isoforms and pharmacological inhibition could 
damage normal cells almost equally. In this regard, 
Figure 9. Dual inhibition of GSTπ and TXNRD delayed tumor formation and growth in vivo. Colorectal cancer tissue- originated spheroids (CTOSs) 
were incubated with auranofin 0.5 μmol/L + piperlongumine 5 μmol/L for 7 days. (A) Drug- resistant CTOSs retained spheroid structure (AP) similar to 
untreated (ϕ) CTOSs. (B) Pairwise comparison of tumor formation between untreated (ϕ) and dual inhibition (AP). (C) Collected tumors. (D) Tumor 
weights after collection (P = 0.008 by paired t test) Scale bar: 100 μm. TXNRD, thioredoxin reductase.
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targeting more cancer- specific glutathione system subunits 
(i.e., GSTs) is more feasible therapeutic option. Indeed, 
piperlongumine activated NRF2 in CTOSs but not in 
fibroblasts, suggesting that GSTπ inhibition is more det-
rimental against cancer cells due to GSTP1 up- regulation 
(Figs. 1, S5 and S6). We verified that combining piper-
longumine and auranofin is a promising alternative, but 
piperlongumine has additional off- target effects [18, 28]. 
In addition, we do not exclude the possibility that other 
up- regulated GST isoforms (α1, α2, μ4, or ο2, Fig. 1) 
are superior target to GSTπ. Developing more specific 
GSTπ inhibitor or inhibitors against other CRC- specific 
GSTs could further refine the specificity.
Previously, we reported that NRF2 is activated and up- 
regulates PPP enzymes in HCC specimens [6]. More 
recently, we identified the p62 phosphorylation as a poten-
tial cause of constitutive activation of NRF2 [29]. 
Considering the fact that NRF2 is frequently activated 
during carcinogenesis by point mutations and other epi-
genetic alteration [30, 31], it was rather surprising that 
colorectal CTOSs displayed apparently physiological NRF2 
response against oxidative stress (this study). We observed 
that basal NRF2 phosphorylation was higher in CTOSs 
compared to fibroblasts (Fig. S5), and up- regulated GST 
isoforms are known NRF2 target genes (Fig. 1). Data 
collectively indicate the possibility that CRC cells increase 
basal level of NRF2 activity but still retain the potential 
of further up- regulation. Thus, regulation of NRF2 could 
not be explained by binary switch (i.e., on or off), but 
be explained by gradual increase for fine- tuning of the 
redox potential.
Finally, we propose the existence of another mechanism 
of drug resistance against redox inhibition. While we 
refined the specificity and effectiveness of redox inhibition 
against CSCs, it was difficult to completely eliminate them. 
A small subpopulation of CTOSs persistently survived 
GSTπ/TXNRD dual inhibition despite accumulated double- 
strand DNA breaks (H2A.X, Figs. 7 and S8). Importantly, 
we confirmed that the dual inhibition lowered CD44v9 
surface presentation (Fig. 8) and delayed the tumor emer-
gence in nude mouse (Fig. 9). However, survived “persist-
ers” still retained lesser but significant tumorigenicity, 
indicating that decreased CD44v9 does not necessarily 
mean the complete remission. Therefore, GSTπ/TXNRD 
dual inhibition preferentially killed CSCs but nevertheless 
the treatment was not enough to eradicate them com-
pletely. We selectively used CTOS cells especially malignant 
in terms of nude mouse tumorigenesis and CD44v9 pres-
entation. Such experimental system could mimic in vivo 
phenomena that distant metastasized cancer cells survive 
ROS insults induced by radiation or chemotherapy (pan- 
resistance). How such “persisters” survive intensive ROS 
insults should be addressed in the future.
Conclusions
Colorectal CTOSs up- regulated five GST isoforms, but 
inhibition of one of them (GSTπ) displayed modest 
cancer- specific cytotoxicity. Inhibition of either GSTπ or 
TXNRD up- regulates NRF2 target genes to compensate 
the other. Dual inhibition results in synergistic cell death 
in CTOSs, expanding the window of “selective killing of 
cancer cells”. The dual inhibition successfully decreased 
CD44v9 surface presentation, and delayed the tumor 
emergence in vivo. However, a small number of “persist-
ers” survived the synergistic cell death despite accumulated 
DNA damage and retained lesser but significant 
tumorigenicity.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. Schematic diagram of pharmacological inhibi-
tion of redox regulation.
Figure S2. CD44v9 is colocalized with GSTP1 and TXNRD1.
Figure S3. Intracellular ROS is higher in fibroblasts than 
in CRC cell lines. Inhibitors of redox regulation increase 
the ROS in CRC cell lines.
Figure S4. Strategy of gating CD44v9positive population 
and defining CD44v9low or CD44v9high.
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Figure S5. Pharmacological inhibition of redox regulation 
induced NRF2 phosphorylation by inhibitors in colorectal 
CTOSs.
Figure S6. Pharmacological inhibition of redox regulation 
up- regulated NRF2 target genes, but not TP53 target genes, 
in human fibroblasts.
Figure S7. Pharmacological inhibition of redox regulation 
failed to alter expression of TP53 target genes in colorectal 
cancer CTOSs.
Figure S8. Prolonged incubation of GSTπ/TXNRD inhibi-
tors induces double- strand DNA breaks in survived colo-
rectal CTOS cells.
Table S1. Sequences of oligos and fluorescent probes used 
in this study.
Table S2. Expression profiles of 17 classes of GST.
Table S3. Inhibition of GSTπ and/or TXNRD on cellular 
survival of embryonic fibroblasts.
